Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| Fasoracetam | NSI-189 | |
|---|---|---|
| Category | Nootropics | Nootropics |
| Standard Dose | 20-100 mg 1-3 times daily (sublingual or oral) | 40 mg once daily (for educational context — investigational compound, not approved for any indication) |
| Timing | Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food. | Once daily, time of day not definitively established from clinical data. With or without food. |
| Cycle Duration | Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data. | Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable. |
| Evidence Level | animal_plus_anecdotal | moderate_human |
Non-classical racetam that modulates all three groups of metabotropic glutamate receptors (mGluR Groups I, II, and III) and upregulates GABA-B receptors — a unique mechanism that distinguishes it from other racetams. Also enhances high-affinity choline uptake (HACU) and stimulates acetylcholine release. Does not significantly affect adrenergic, serotonergic, or dopaminergic receptors. The GABA-B upregulation is particularly notable as it may counteract GABA-B receptor downregulation caused by phenibut or baclofen tolerance.
20-100 mg 1-3 times daily (sublingual or oral)
Morning and afternoon. Sublingual administration may provide faster onset and higher bioavailability. With or without food.
Cycles of 4-8 weeks on, 2-4 weeks off. Limited long-term safety data.
Benzylpiperizine-aminopyridine compound that stimulates neurogenesis of human hippocampus-derived neural stem cells in vitro and increases hippocampal volume in vivo. Mechanism is independent of serotonin or norepinephrine reuptake inhibition — fundamentally distinct from traditional antidepressants. Activates the TrkB receptor (BDNF receptor) and downstream Akt/PI3K signaling pathways to promote synaptic plasticity, long-term potentiation, and neuronal survival. Enhances BDNF expression in hippocampal subregions critical for memory consolidation and mood regulation. Originally developed as ALTO-100 (Alto Neuroscience) for treatment-resistant depression with cognitive impairment.
40 mg once daily (for educational context — investigational compound, not approved for any indication)
Once daily, time of day not definitively established from clinical data. With or without food.
Phase 2 trial used 12-week treatment duration. Long-term safety data unavailable.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →